RxDoctor Payments Data

Andrew Imparato, MD

Family Medicine · Fullerton, CANPI 1720400971

Payments from drug & device makers

$1,495in general payments, 2019–2025

Across 47 payments — averaging $31.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$453
  • Lilly USA, LLC$270
  • Neurocrine Biosciences, Inc.$254
  • Boston Scientific$108
  • Teva Pharmaceuticals USA, Inc.$87
  • Novo Nordisk$59
  • plus $264 from 9 others

What the payments were for

  • Food & beverage$1,40894%
  • Education$876%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,495 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$409,281
Medicare patients
798
Services billed
4,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban853$274,779
IngrezzaValbenazine Tosylate32$138,404
Austedo XrDeutetrabenazine13$133,495
XareltoRivaroxaban202$68,121
XifaxanRifaximin30$54,970
JanuviaSitagliptin Phosphate65$23,724
SantylCollagenase Clostridium Hist.22$20,138
OzempicSemaglutide19$18,505
Pantoprazole Sodium306$18,142
Baclofen96$15,603
TrulicityDulaglutide12$14,582
EntrestoSacubitril/Valsartan42$14,168
Atorvastatin Calcium839$12,989
MounjaroTirzepatide13$11,772
LinzessLinaclotide20$11,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$24$274,779853 claims
Neurocrine Biosciences, Inc.Ingrezza$254$138,40432 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$87$133,49513 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$270$34,578271 claims
Novo NordiskOzempic$59$18,50519 claims
NovartisEntresto$15$14,16842 claims
Boehringer IngelheimJardiance$19$10,74536 claims
AstraZenecaFarxiga$40$9,22916 claims
Sumitomo Pharma America, Inc.Gemtesa$24$7,15227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →